Why $2.5B in IVD revenue is a structural challenge, not a checkbook problem
Diagnostics is one of the few medical-device categories where greenfield startups simply don't reach mid-cap scale — not because R&D is uniquely hard, but because the customers won't switch. Hospital labs run 20–40-year installed bases on Roche, Abbott, Beckman, and Siemens. A new vendor needs not just product, but trust that takes a generation to build.
Build it from scratch
Develop four regulated platforms (chemistry, immunoassay, POC, molecular) in-house, build GMP manufacturing, run clinical trials, win FDA / IVDR / NMPA approvals, and stand up a global salesforce. Theoretically possible. Has effectively never been done at this scale.
Acquire your way to scale
Buy an anchor platform (Vitros-class), then bolt on POC, molecular, and blood-typing assets. This is literally the QDEL playbook: Quidel ($800M) + Ortho ($2B) = $2.7B. Fast revenue scaling; inherits cyclicality, debt, and integration risk simultaneously.
Buy one core, build around it
Acquire one mature reagent-rental platform doing $1–1.5B, then organically grow menu, geography, and adjacent franchises over a decade. The Hologic playbook (Cytyc → Gen-Probe → organic). Lower capital, longer timeline, fewer integration scars.
The structural reasons no one does this anymore
Money isn't the constraint — customer adoption is. Central-lab buyers won't validate a brand-new vendor for a core analyzer, and the regulatory clock alone (5–8 years per platform) is longer than most VC fund cycles. Modern attempts at greenfield-style IVD scale (Theranos, Cue Health) failed catastrophically.
| Cost bucket | Per platform | Why it's hard |
|---|---|---|
| R&D to first 510(k) / PMA approval | $200–500M | 5–8 years per major platform; ×4 platforms = 20+ years if sequential |
| GMP manufacturing facilities | $150–400M | Reagents are tightly controlled; can't outsource at scale |
| Clinical trial infrastructure | $50–200M / assay | PMA-class molecular assays need multi-site clinical programs |
| Regulatory: FDA + CE-IVDR + NMPA + PMDA | $50–100M | EU IVDR transition has bankrupted small EU players outright |
| Global commercial buildout | $400–700M | ~1,500 reps + service techs across 30+ countries |
| Working capital (reagent-rental model) | $300–500M | Front-load instruments to capture multi-year reagent annuity |
| Brand & customer trust | Unquantifiable | Hospitals don't switch core lab to a 3-year-old vendor |
| Total capital deployed (×4 platforms) | $8–15B | Realistic ceiling at year 15: $200–500M revenue |
Adoption, not technology
Roche, Abbott, Beckman, and Siemens have 20–40-year installed bases. The sales cycle for a core lab analyzer is 18–36 months even for known vendors with reference sites. A startup gets nowhere near $2.5B before competitors close ranks on its niche.
This is why the only modern attempts at greenfield-style IVD scale have failed: Theranos, Cue Health, GenMark, and many others. The graveyard is large.
Single-franchise, single-vertical
Greenfield can work for one platform, one customer segment. IDEXX (veterinary), Natera (NIPT), Guardant (liquid biopsy) all built single-franchise IVD companies organically — but each one bypassed the central lab entirely.
For a multi-platform QDEL-equivalent, greenfield is essentially impossible. The realistic answer for someone trying greenfield isn't "build a $2.5B company" — it's "build a $300–600M one and sell."
The fastest path to revenue — and the riskiest path to value creation
The only proven way to assemble a multi-platform $2.5B IVD player. It works for getting to revenue scale (Quidel + Ortho got there in seven months). Whether it works for creating shareholder value is a separate question, and right now QDEL's $1B market cap is the unflattering answer.
| Step | EV | Revenue added |
|---|---|---|
| Anchor platform (Vitros-equivalent core lab) Public mid-cap or PE-owned IVD company; reagent-rental annuity | $5–7B | $1.5–2.0B |
| Bolt-on POC franchise Quidel-class rapid testing + immunoassay | $1.5–2.5B | $400–700M |
| Molecular platform tuck-in LEX-style POC PCR or NGS-prep startup | $300–600M | $50–150M |
| Specialty / blood-typing tuck-in Immunohematology or transfusion screening franchise | $500M–1B | $200–400M |
| Integration costs + dis-synergies ERP unification, redundancies, year-1 disruption | $500–700M | — |
| Total deployed | $7.8–11.8B | ~$2.5B revenue |
Why ~50/50 debt/equity is standard
IVD reagent-rental cash flows are stable enough to support meaningful leverage. Quidel financed the 2022 deal with roughly half debt, half equity. Replicating today: raise $4–6B equity and find lenders to extend $4–6B in term debt secured by combined cash flows.
Doable in a normal credit environment. Nearly impossible in a tight one — which is partly why QDEL was forced to refinance in 2025 rather than negotiate from strength.
Revenue achieved, value not created
QDEL took on ~$2.5B of acquisition debt in 2022 to acquire Ortho. The combined revenue arrived; the synergies and topline trajectory underperformed. The COVID windfall reversed. Goodwill was impaired by $701M in Q3 2025.
$11.5B of EV deployed in 2022 is now valued at ~$3.6B EV ($1B equity + $2.6B debt). That's the risk of the roll-up path: you can buy revenue, but the market re-rates the multiple.
The Hologic playbook — patient capital, organic compounding
Buy one mature reagent-rental platform with $1–1.5B in revenue and a defensible installed base. Then organically grow menu, geography, and adjacent franchises over 8–10 years. Less leverage, less integration risk, but requires patient shareholders increasingly hard to find.
| Step | Cost | Revenue path |
|---|---|---|
| Acquire mid-scale platform with sticky installed base Year 1 — anchor with $1.0–1.5B revenue, EBITDA-positive day one | $4–6B EV | $1.0–1.5B |
| Organic R&D + menu expansion Years 2–7 — drive existing platform from $1B → $1.8B | $600M–1B (cumulative) | +$800M |
| In-license or develop one adjacent vertical Years 4–8 — POC molecular, NGS prep, or specialty Dx | $300–600M | +$200–400M |
| Geographic expansion (China, EU, EM) Years 3–10 — incremental commercial buildout | $400–700M | +$200–300M |
| Working capital + bolt-on optionality Reserve for one transformative deal in years 8–10 | $300–500M | +$300–500M |
| Total deployed | $5.6–8.8B | $2.0–2.7B |
Compound growth on a sticky installed base
Reagent-rental IVD platforms throw off 20–25% margins and grow menu organically at MSD–HSD rates. Compounded over a decade, a $1.2B platform becomes $2B without acquisition risk. Margin expands as menu broadens. Customer lock-in deepens.
The leverage profile is fundamentally healthier: smaller acquisition debt, more cash generation, no integration hangover. You stay closer to 2.5–3.0× through the cycle.
Patience is the scarce resource
Public markets have grown intolerant of decade-long compounding stories without acquisition catalysts. A management team telling investors "we'll get to $2.5B in 10 years organically" gets replaced by an activist who wants the M&A path within two.
This path realistically requires either a private-company structure, a controlling family/founder owner, or a strategic acquirer's balance sheet (i.e., this is what Roche/Abbott divisions look like internally).
The three paths on every dimension that matters
The numbers below are mid-point estimates. The probability columns reflect base-rate odds based on historical IVD M&A and greenfield outcomes — not specific to any one team's execution capability.
| 01 Greenfield | 02 Roll-up | 03 Hybrid | |
|---|---|---|---|
| Capital required | $8–15BR&D, manufacturing, regulatory, commercial | $8–12BMostly acquisition price + integration | $5–9BAnchor deal + organic R&D over a decade |
| Time to $2.5B | Effectively neverRealistic ceiling: $200–500M at year 15 | 3–5 yearsTwo big deals, fast scale | 8–12 yearsOne anchor + organic compounding |
| Funding mix | Mostly equity / VCCan't lever a pre-revenue business | ~50/50 debt/equityStable cash flows support leverage | Mostly equity, modest debt2.5–3.0× through cycle |
| P(reaching scale) | <5%Theranos / Cue Health graveyard | 60–70%Revenue almost certainly arrives | 40–50%Patience risk; activist exposure |
| P(value creation) | <5%Same as above | ~30%QDEL is the active counter-example | ~45%Best risk-adjusted path |
| Key risk | Customer adoptionHospitals won't switch to a startup | Integration + leverageSynergies under-deliver, debt overhangs | Talent + patienceDecade-long story; activist intervention |
| Best modern example | None at this scaleIDEXX did it for vet; not human Dx | QuidelOrtho 2022Cautionary tale in progress | HologicCytyc → Gen-Probe → organic menu growth |
| Most likely exit | Failure or asset saleSelling tech to a strategic | Stay independent or sell at distressPath looks like QDEL today | IPO or strategic sale at premiumRe-rate as franchise compounds |
The honest answer is don't build a $2.5B IVD company at all
Every viable path to a QDEL-scope franchise costs roughly the same as buying the existing one — and the existing one is currently worth a fraction of what the market thought three years ago. The better question is: what scale and franchise does create value, and how do you get there with capital you can actually raise?
Build for $300–600M revenue in a focused franchise
This is where IDEXX, Natera, Guardant, Veracyte, and pre-merger Quidel all played. A focused single-franchise IVD company — POC molecular only, oncology Dx only, veterinary Dx only — can be built for $1.5–3B of capital, reach scale in 6–8 years, and either stay independent at a premium multiple or get acquired by a strategic at a strategic premium. The capital math works.